SIAH2 suppresses c‐ JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Qinghe Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digestive Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Cell Proliferation, Hepatitis B virus, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Provincial Commission of Health and Family Planning, Young Science and Technology Innovation Team of Xuzhou Medical University Key Research and Development Plan of Jiangsu Province, Basic Research Program of Jiangsu Province.
Abstract (Originalsprache)
As an important protein encoded by hepatitis B virus (HBV), HBV X protein (HBx) plays an important role in the development of hepatocellular carcinoma (HCC). It has been shown that seven in absentia homologue 1 (SIAH1) could regulates the degradation of HBx through the ubiquitin‐proteasome pathway. However, as a member of SIAH family, the regulatory effects of SIAH2 on HBx remain unclear. In this study, we first confirmed that SIAH2 could reduce the protein levels of HBx depending on its E3 ligase activity. Moreover, SIAH2 interacted with HBx and induced its K48‐linked polyubiquitination and proteasomal degradation. Furthermore, we provided evidence that SIAH2 inhibits HBx‐associated HCC cells proliferation by regulating HBx. In conclusion, our study identified a novel role for SIAH2 in promoting HBx degradation and SIAH2 exerts an inhibitory effect in the proliferation of HBx‐associated HCC through inducing the degradation of HBx. Our study provides a new idea for the targeted degradation of HBx and may have great huge significance into providing novel evidence for the targeted therapy of HBV‐infected HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Digestive Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Research Center of Digestive Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Central Laboratory, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
ORCID-Profile: Zhiyi Liu, Hengliang Shi
Förderung
- Jiangsu Provincial Commission of Health and Family Planning
- Young Science and Technology Innovation Team of Xuzhou Medical University Key Research and Development Plan of Jiangsu Province
- Basic Research Program of Jiangsu Province
Zitieren
APA
Hu, Q., Liu, Z., Liu, Y., Qiu, J., Zhang, X., Sun, J., Zhang, B., & Shi, H. (2024). SIAH2 suppresses c‐ JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18484
Vancouver
Hu Q, Liu Z, Liu Y, Qiu J, Zhang X, Sun J, et al. SIAH2 suppresses c‐ JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18484
BibTeX
@article{Hu2024,
author = {Hu, Qinghe and Liu, Zhiyi and Liu, Yao and Qiu, Jie and Zhang, Xue and Sun, Jun and Zhang, Bin and Shi, Hengliang},
title = {SIAH2 suppresses c‐ JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18484}
}
EUVIMED